GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adhera Therapeutics Inc (OTCPK:ATRX) » Definitions » Forward Dividend Yield %

Adhera Therapeutics (Adhera Therapeutics) Forward Dividend Yield % : 0.00% (As of Apr. 30, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Adhera Therapeutics Forward Dividend Yield %?

As of today (2024-04-30), the Forward Annual Dividend Yield of Adhera Therapeutics is 0.00%.

As of today (2024-04-30), the Trailing Annual Dividend Yield of Adhera Therapeutics is 0.00%.

ATRX's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.45
* Ranked among companies with meaningful Forward Dividend Yield % only.

Adhera Therapeutics's Dividends per Share for the three months ended in Sep. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Adhera Therapeutics's Forward Dividend Yield %

For the Biotechnology subindustry, Adhera Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adhera Therapeutics's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adhera Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Adhera Therapeutics's Forward Dividend Yield % falls into.



Adhera Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Adhera Therapeutics  (OTCPK:ATRX) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Adhera Therapeutics Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Adhera Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Adhera Therapeutics (Adhera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8000 Innovation Parkway, Baton Rouge, LA, USA, 70820
Adhera Therapeutics Inc is an emerging specialty biotech company that is strategically evaluating its focus including a return to a drug discovery and development company.
Executives
Zahed Subhan director 8000 INNOVATION PARKWAY, BATON ROUGE LA 70820
Trond Kydd Waerness director 8000 INNOVATION PARKWAY, BAON ROUGE LA 70820
Rice Charles L Jr director C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk director, officer: Chief Executive Officer 549 MILGATE PLACE, BATON ROUGE LA 70810
Rhonda L. Stanley officer: SVP Finance & Accounting 5001 SOUTH MIAMA BOULEVARD, SUITE 300, DURHAM NC 27703
Nancy R. Phelan director 812 MAPLEWOOD ROAD, WAYNE PA 19087
Robert Eric Teague officer: Chief Financial Officer C/O MARINA BIOTECH, INC., 4721 EMPEROR BOULEVARD, SUITE 350, DURHAM NC 27703
Uli Hacksell director 3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Robert Jr. Moscato officer: CEO 400 PRATT STREET, SUITE 606, BALTIMORE MD 21202
Timothy Boris director 805 AEROVISTA PLACE, SUITE 205, SAN LUIS OBISPO CA 93401
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Peter D. Weinstein officer: Chief Legal Officer C.O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Amit B. Shah officer: Chief Financial Officer 10 AGUILA, ALISO VIEJO CA 92656
Erik C. Emerson officer: Chief Commercial Officer 2300 WEST SAHARA AVENUE, SUITE 800 - #4012, LAS VEGAS NV 89102
Mihir Munsif officer: Chief Operating Officer 21102 BRIARWOOD LANE, TRABUCO CANYON CA 92679